AstraZeneca says its blockbuster Farxiga proved to be a game-changer in CKD — wrapping PhIII early
If the FDA can still hold up its end of the bargain, AstraZeneca is already on a short path to scooping up a cutting-edge win with a likely approval for their SGLT2 drug Farxiga in cutting the risk of heart failure. Now the pharma giant says it can point to solid evidence that the drug — initially restricted to diabetes — also works for chronic kidney disease, potentially adding a blockbuster indication for the franchise.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,600+ biopharma pros reading Endpoints daily — and it's free.